Nilotinib, Imatinib

DRUG2 trials

Sponsors

Novartis Pharmaceuticals, Seoul St. Mary's Hospital

Conditions

Chronic Myeloid LeukemiaGastrointestinal Stromal Tumors

Phase 1

Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib

CompletedNCT00441155

Novartis PharmaceuticalsGastrointestinal Stromal Tumors

Start: 2006-11-30End: 2011-01-31Updated: 2013-05-13

Phase 3

Efficacy of Nilotinib Versus Imatinib in Ph+ CML in Early CP Who Have a Suboptimal Molecular Response to Imatinib

Seoul St. Mary's HospitalChronic Myeloid Leukemia

Start: 2009-01-31End: 2014-06-30Target: 100Updated: 2014-01-13